Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Institut de Recherches Internationales Servier
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Effect of Memantine 20 mg (Ebixa) and Donepezil 5 mg (Aricept) on motor cortex plasticity induced by paired associative stimulation using transcranial magnetic stimulation (TMS) in patients suffering from Mild Cognitive Impairment. A phase II monocentric, double-blind, randomised, placebo-controlled, parallel group study
To assess the potential effects of one month of repeated administration of donepezil and memantine compared to placebo on motor cortex plasticity induced by paired associative stimulation using transc...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Efficacy and safety of S38093 versus placebo, in co-administration with donepezil in patients with moderate Alzheimer's disease. Effektivitet och säkerhet av S38093 mot placebo, som tilläggsbehandling till donepezil hos patienter med måttlig Alzheimers sjukdom
To assess the efficacy of 3 fixed doses of S 38093 (2, 5 and 20mg/ day) versus placebo, in co-administration with donepezil 10 mg/day, after 24 weeks of treatment, on cognitive performance measured ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of a background therapy with atenolol in patients with stable angina pectoris. A 4-month randomised double-blind parallel-group international multicentre study
To demonstrate that after a 4-month treatment period ivabradine (5 mg b.i.d. given orally for 2 months then 7.5 mg b.i.d. given orally for other 2 months) is more efficacious than placebo when given i...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
A phase 2 study evaluating S 95005 plus bevacizumab and capecitabine plus bevacizumab in patients with previously untreated colorectal cancer who are non-eligible for intensive therapy
To evaluate the progression-free survival (PFS) in patients receiving S 95005 + bevacizumab (experimental arm) or capecitabine + bevacizumab (control arm) as first-line treatment for unresectable meta...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Evaluation of the reduction in heart rate, of the quantity of drug in the plasma and of the safety after different ascending oral doses of the active substance or a placebo in heart failure patients with a reduction of left ventricular ejection fraction (i.e. the quantity of blood the heart is able to eject in the body at each heart beat)
To evaluate the pharmacodynamics in relation to resting heart rate (HR) of two different schemes of starting doses and two step titration doses of S 38844 versus placebo in patients with moderate to s...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier (France)
MAJ Il y a 4 ans
ObsErvationAl Study to analYse titration of the new Diamicron MR 60 mg formulation in daily clinical practice in a large population with uncontrolled type 2 diabetes
Background and study aims Gliclazide is a well-known drug prescribed to control glucose levels in patients with type 2 diabetes mellitus. Diamicron MR 60 mg is a new modified-release formulation of gl...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier (I.R.I.S)
MAJ Il y a 4 ans
Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson Disease patients with motor fluctuations: a 4-week open label pilot study
Assessment of the acceptability of a sublingual formulation of piribedil
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 5 ans
A randomised, double-blind, placebo- and olanzapine- controlled, parallel-group study to evaluate the efficacy and safety of 3 fixed doses of S 33138 in treatment of patients with an acute episode of Schizophrenia. A phase IIb, international, multicentre, 8-week study
To assess the antipsychotic efficacy of S 33138 compared to placebo
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Efficacy and safety of tianeptine oral administration (25 to 50 mg/day) in elderly patients suffering from Major Depressive Disorder. A 8-week, randomized, double-blind, flexible-dose, parallel groups, placebo-controlled, international, multicentre study with escitalopram as active control, followed by an optional double-blind extension treatment period of 16 weeks
To demonstrate the antidepressant efficacy of an 8-week tianeptine oral administration in elderly out-patients suffering from Major Depressive Disorder compared to placebo. The assay sensitivity will ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier (France)
MAJ Il y a 4 ans
Observational cohort study to evaluate the safety of agomelatine in standard medical practice in depressed patients
Not provided at time of registration and not expected to be available in the future
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant